Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

72.31 +0.97 (+1.36%)
Streaming Delayed Price Updated: 12:39 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 298,668
Open 71.63
Bid (Size) 72.26 (1)
Ask (Size) 72.34 (2)
Prev. Close 71.34
Today's Range 71.45 - 72.62
52wk Range 29.42 - 117.33
Shares Outstanding 115,926,629
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Russell 2000 Stocks in Hot Water
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the... 
Via StockStory
CORCEPT THERAPEUTICS INC (NASDAQ:CORT) – A Strong Growth Stock with Technical Breakout Potential
CORCEPT THERAPEUTICS INC (NASDAQ:CORT) shows strong growth fundamentals and a bullish technical setup, making it a candidate for growth investors. High revenue growth, profitability, and a debt-free... 
Via Chartmill

Performance

YTD
+44.7%
+44.7%
1 Month
+0.9%
+0.9%
3 Month
-13.7%
-13.7%
6 Month
+44.7%
+44.7%
1 Year
+129.1%
+129.1%

More News

Read More
Corcept Presents Data from Treatment Phase of CATALYST Trial at American Diabetes Association’s 85th Scientific Sessions with Simultaneous Publication in Diabetes Care
From Corcept Therapeutics Incorporated
Via Business Wire
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Corcept Therapeutics Therapy Fails Primary Goal But Extends Patient Survival In Amyotrophic Lateral Sclerosis Study
Via Benzinga
Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting
From Corcept Therapeutics Incorporated
Via Business Wire
2 Profitable Stocks to Target This Week and 1 to Avoid
Via StockStory
Corcept Presents Pivotal Clinical Data in ASCO Late-Breaker with Simultaneous Publication in The Lancet: Relacorilant Improves Progression-Free and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
From Corcept Therapeutics Incorporated
Via Business Wire
1 Cash-Heavy Stock on Our Watchlist and 2 to Steer Clear Of
Via StockStory
Here's How Much $1000 Invested In Corcept Therapeutics 5 Years Ago Would Be Worth Today
Via Benzinga
1 Growth Stock with All-Star Potential and 2 to Avoid
Via StockStory
Topics Artificial Intelligence
CORCEPT THERAPEUTICS INC (NASDAQ:CORT) – A Strong Growth Stock with Technical Breakout Potential
Via Chartmill
Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Corcept (NASDAQ:CORT)
Via StockStory
Topics Artificial Intelligence Intellectual Property
CORT Q1 Earnings Call: Pharmacy Disruptions Overshadow Prescription Growth, Guidance Reaffirmed
Via StockStory
Here's How Much You Would Have Made Owning Corcept Therapeutics Stock In The Last 5 Years
Via Benzinga
Looking for growth without the hefty price tag? Consider CORCEPT THERAPEUTICS INC (NASDAQ:CORT).
Via Chartmill
How Do Investors Really Feel About Corcept Therapeutics?
Via Benzinga
Will CORCEPT THERAPEUTICS INC (NASDAQ:CORT) breakout?
Via Chartmill
1 Small-Cap Stock Worth Your Attention and 2 to Question
Via StockStory
Assessing Corcept Therapeutics: Insights From 9 Financial Analysts
Via Benzinga
Corcept Therapeutics Stock Jumps On Record Prescription Volume: Retail Sentiment Soars
Via Stocktwits
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Corcept (NASDAQ:CORT) Misses Q1 Sales Targets, Stock Drops
Via StockStory
Topics Artificial Intelligence
Top movers in Monday's after hours session
Via Chartmill
CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
From Corcept Therapeutics
Via Business Wire

Frequently Asked Questions

Is Corcept Therapeutics Incorporated - Common Stock publicly traded?
Yes, Corcept Therapeutics Incorporated - Common Stock is publicly traded.
What exchange does Corcept Therapeutics Incorporated - Common Stock trade on?
Corcept Therapeutics Incorporated - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Corcept Therapeutics Incorporated - Common Stock?
The ticker symbol for Corcept Therapeutics Incorporated - Common Stock is CORT on the Nasdaq Stock Market
What is the current price of Corcept Therapeutics Incorporated - Common Stock?
The current price of Corcept Therapeutics Incorporated - Common Stock is 72.31
When was Corcept Therapeutics Incorporated - Common Stock last traded?
The last trade of Corcept Therapeutics Incorporated - Common Stock was at 07/03/25 12:39 PM ET
What is the market capitalization of Corcept Therapeutics Incorporated - Common Stock?
The market capitalization of Corcept Therapeutics Incorporated - Common Stock is 8.38B
How many shares of Corcept Therapeutics Incorporated - Common Stock are outstanding?
Corcept Therapeutics Incorporated - Common Stock has 8B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.